Related Experiment Video
Updated: May 21, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
5.9K
Acquired Hemophilia-A Case Series and Review
Liat Waldman Radinsky1, Maayan Sivan2,3, Aharon Lubetsky1,4
1National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel.
Journal of Clinical Medicine
|March 17, 2025
Summary
Acquired hemophilia A (AHA) treatment involves immunosuppressive therapy, with Emicizumab showing promise for refractory cases. Most patients achieve remission, but careful monitoring for side effects is crucial.
Area of Science:
- Hematology
- Autoimmune Diseases
- Clinical Research
Background:
- Acquired hemophilia A (AHA) is a rare, life-threatening autoimmune disorder.
- Characterized by autoantibodies against factor VIII (FVIII), leading to bleeding.
- This study reviews a single-center cohort for insights into AHA.
Purpose of the Study:
- To evaluate patient characteristics, treatments, and outcomes in acquired hemophilia A.
- To assess the efficacy and safety of different therapeutic strategies.
- To identify factors influencing remission and recurrence rates.
Main Methods:
- Retrospective review of 22 adult patients diagnosed with AHA (2012-2024).
- Data collection included demographics, clinical presentation, laboratory findings, treatments, and outcomes.
- Statistical analysis compared genders and evaluated treatment strategies and remission outcomes.
Main Results:
- Equal gender distribution, average age 62; common etiologies: idiopathic (45%), pregnancy (27%), malignancy (23%).
- Initial immunosuppressive therapy (IST) achieved 45% remission; Emicizumab showed promise in a refractory case.
- 64% achieved remission within 3 months; 14% recurrence rate; no thrombotic events, but corticosteroid side effects noted.
Conclusions:
- IST is the primary treatment for AHA, requiring individualized care due to side effects.
- Emicizumab offers potential benefits for refractory AHA patients and fragile populations.
- Further research is needed on long-term outcomes and spontaneous remission, especially in specific populations.
Related Concept Videos
01:19X-linked Traits
52.5K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
52.5K
01:24Disorders of Hemostasis
673
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
673
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
01:05Introduction to Hemostasis
4.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.7K
01:11Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
02:45Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K